Stock Events

Stock Events

Trevi Therapeutics 

$11.05
0
+$0.41+3.85% Tuesday 02:56

Statistics

Day High
11.05
Day Low
11.05
52W High
-
52W Low
-
Volume
300
Avg. Volume
-
Mkt Cap
1.42B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q3 2025
Q4 2025
Next
-0.1
-0.09
-0.07
-0.06
Expected EPS
-0.076667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-95.82MNet Income

Analyst Ratings

$20.56Average Price Target
The highest estimate is 24.00.
From 9 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow TRVI.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is a competitor because it also develops treatments for serious diseases, potentially overlapping with Trevi's focus areas.
Biogen
BIIB
Mkt Cap22.63B
Biogen competes in the neurology space, which may intersect with Trevi's therapeutic areas.
Alkermes
ALKS
Mkt Cap5.07B
Alkermes competes in the area of central nervous system diseases, similar to Trevi's focus.
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Acadia Pharmaceuticals targets central nervous system disorders, aligning with Trevi's market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a broad portfolio that could compete with Trevi's treatments in overlapping disease areas.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries has a wide range of products that could compete with Trevi's pipeline.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals has a focus on neurological disorders, potentially competing with Trevi.
Novartis
NVS
Mkt Cap237.61B
Novartis offers medications in various therapeutic areas, including those that could compete with Trevi's.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie's broad focus on serious diseases includes areas that may overlap with Trevi's therapeutic targets.

About

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Show more...
CEO
ISIN
US89532M1018

Listings

XNAS
US
TRVI
BOATS
BOATS
TRVI.BOATS

0 Comments

Share your thoughts

FAQ

What is Trevi Therapeutics stock price today?▼
The current price of TRVI.BOATS is $11.05 USD — it has increased by +3.85% in the past 24 hours. Watch Trevi Therapeutics stock price performance more closely on the chart.
What is Trevi Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Trevi Therapeutics stocks are traded under the ticker TRVI.BOATS.
What is Trevi Therapeutics market cap?▼
Today Trevi Therapeutics has the market capitalization of 1.42B
When is the next Trevi Therapeutics earnings date?▼
Trevi Therapeutics is going to release the next earnings report on May 07, 2026.
What were Trevi Therapeutics earnings last quarter?▼
TRVI.BOATS earnings for the last quarter are -0.06 USD per share, whereas the estimation was -0.1 USD resulting in a +37.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Trevi Therapeutics revenue for the last year?▼
Trevi Therapeutics revenue for the last year amounts to 0 USD.
What is Trevi Therapeutics net income for the last year?▼
TRVI.BOATS net income for the last year is -95.82M USD.
When did Trevi Therapeutics complete a stock split?▼
Trevi Therapeutics has not had any recent stock splits.